FY2016 Earnings Forecast for Sanofi (SNY) Issued By Jefferies Group
Sanofi (NYSE:SNY) – Research analysts at Jefferies Group lowered their FY2016 earnings per share estimates for Sanofi in a research note issued to investors on Thursday. Jefferies Group analyst J. Holford now expects that the firm will post earnings per share of $2.95 for the year, down from their previous estimate of $3.06. Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for Sanofi’s FY2017 earnings at $2.93 EPS, FY2018 earnings at $3.17 EPS, FY2019 earnings at $3.60 EPS and FY2020 earnings at $4.06 EPS.
Several other brokerages have also recently issued reports on SNY. TheStreet upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Wednesday, July 27th. Zacks Investment Research upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Berenberg Bank restated a “hold” rating and issued a $93.00 price target on shares of Sanofi in a research report on Monday, August 15th. BNP Paribas upgraded shares of Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Sanofi in a research note on Thursday, September 15th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $60.50.
Shares of Sanofi (NYSE:SNY) traded up 0.08% during midday trading on Friday, reaching $37.76. 1,635,370 shares of the company’s stock traded hands. The company has a 50 day moving average of $38.67 and a 200 day moving average of $40.40. The firm has a market cap of $97.19 billion, a PE ratio of 21.08 and a beta of 0.98. Sanofi has a 52-week low of $37.20 and a 52-week high of $51.88.
Hedge funds and other institutional investors have recently modified their holdings of the company. Boston Partners raised its position in Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock worth $309,774,000 after buying an additional 7,330,168 shares during the period. Dodge & Cox raised its position in Sanofi by 7.2% in the first quarter. Dodge & Cox now owns 53,530,129 shares of the company’s stock worth $2,149,770,000 after buying an additional 3,615,056 shares during the period. Hamlin Capital Management LLC acquired a new position in Sanofi during the second quarter worth $56,725,000. Hotchkis & Wiley Capital Management LLC raised its position in Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock worth $478,434,000 after buying an additional 1,267,118 shares during the period. Finally, Senzar Asset Management LLC acquired a new position in Sanofi during the second quarter worth $46,173,000. 9.42% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Company Profile
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.